PMID- 31202168
OWN - NLM
STAT- MEDLINE
DCOM- 20200108
LR  - 20200108
IS  - 1950-6007 (Electronic)
IS  - 0753-3322 (Linking)
VI  - 117
DP  - 2019 Sep
TI  - Association of HLA-C*03:02 with methimazole-induced liver injury in Graves' 
      disease patients.
PG  - 109095
LID - S0753-3322(19)32334-0 [pii]
LID - 10.1016/j.biopha.2019.109095 [doi]
AB  - Methimazole (MMI) has been used for the treatment of Graves' Disease (GD) for 
      more than half a century. The MMI treatment has been reported to be associated 
      with hepatotoxicity. Previous studies have demonstrated that human leukocyte 
      antigen (HLA) genetic polymorphisms were associated with many drugs-induced liver 
      injuries. To investigate HLA genetic susceptibility to MMI-induced liver injury 
      (MMI-DILI), we characterized both HLA class I and class Ⅱ in a well-characterized 
      phenotypic cohort with 40 MMI-DILI cases and 118 MMI-tolerant controls. Among the 
      40 MMI-DILI cases, 57.5% were women and 50% were cholestatic liver damage with 
      occurring time from days to months after MMI dosing. The frequency of HLA-C*03:02 
      was 6.7% (5/75) in the MMI-DILI case patients and 6.4% (4/62) in MMI-induced 
      cholestatic/mixed liver damage, which were significantly different from the 
      percentage of 0.4% (1/231) in the MMI-tolerant patients (odds ratio (OR) = 15.4, 
      95% confidence interval (CI) = 1.77-133.9, adjusted P = 0.0292; OR=14.9, 95% 
      CI=2.38-182.9, adjusted P = 0.0323; respectively). HLA-A*02:01 was also found to 
      be associated with MMI-induced cholestatic/mixed liver injury (OR = 3.13, 
      95%CI=1.45-6.91, adjusted P = 0.0464). The present study demonstrated that 
      individuals carrying HLA-C*03:02 allele are at increased risk of developing 
      MMI-induced DILI. These results may assist doctors to prevent the occurrence of 
      hepatotoxicity in GD patients receiving MMI.
CI  - Copyright (c) 2019 The Authors. Published by Elsevier Masson SAS.. All rights 
      reserved.
FAU - Li, Xuesong
AU  - Li X
AD  - Department of Endocrinology and Metabolism, Minhang Hospital, Fudan University, 
      Shanghai, 201199, PR China.
FAU - Jin, Shasha
AU  - Jin S
AD  - Department of Clinical Pharmacy, School of Pharmacy, Fudan University, Shanghai, 
      201203, PR China.
FAU - Fan, Yujuan
AU  - Fan Y
AD  - Department of Endocrinology and Metabolism, Minhang Hospital, Fudan University, 
      Shanghai, 201199, PR China.
FAU - Fan, Xiaofang
AU  - Fan X
AD  - Department of Endocrinology and Metabolism, Minhang Hospital, Fudan University, 
      Shanghai, 201199, PR China.
FAU - Tang, Zhijia
AU  - Tang Z
AD  - Department of Clinical Pharmacy, School of Pharmacy, Fudan University, Shanghai, 
      201203, PR China.
FAU - Cai, Weimin
AU  - Cai W
AD  - Department of Clinical Pharmacy, School of Pharmacy, Fudan University, Shanghai, 
      201203, PR China.
FAU - Yang, Jialin
AU  - Yang J
AD  - Department of Endocrinology and Metabolism, Minhang Hospital, Fudan University, 
      Shanghai, 201199, PR China. Electronic address: Jialinyang2002@163.com.
FAU - Xiang, Xiaoqiang
AU  - Xiang X
AD  - Department of Clinical Pharmacy, School of Pharmacy, Fudan University, Shanghai, 
      201203, PR China. Electronic address: xiangxq@fudan.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20190612
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
RN  - 0 (HLA-C Antigens)
RN  - 0 (HLA-C*03 antigen)
RN  - 554Z48XN5E (Methimazole)
SB  - IM
MH  - Adult
MH  - Alleles
MH  - Chemical and Drug Induced Liver Injury/*etiology/*genetics
MH  - Female
MH  - Genetic Predisposition to Disease/*genetics
MH  - Graves Disease/drug therapy/*genetics
MH  - HLA-C Antigens/*genetics
MH  - Humans
MH  - Liver/drug effects
MH  - Male
MH  - Methimazole/*adverse effects/therapeutic use
MH  - Polymorphism, Genetic/*genetics
MH  - Retrospective Studies
OTO - NOTNLM
OT  - Drug-induced liver injury
OT  - Human leukocyte antigens
OT  - Methimazole
OT  - Molecular docking
EDAT- 2019/06/16 06:00
MHDA- 2020/01/09 06:00
CRDT- 2019/06/16 06:00
PHST- 2019/05/21 00:00 [received]
PHST- 2019/06/04 00:00 [revised]
PHST- 2019/06/04 00:00 [accepted]
PHST- 2019/06/16 06:00 [pubmed]
PHST- 2020/01/09 06:00 [medline]
PHST- 2019/06/16 06:00 [entrez]
AID - S0753-3322(19)32334-0 [pii]
AID - 10.1016/j.biopha.2019.109095 [doi]
PST - ppublish
SO  - Biomed Pharmacother. 2019 Sep;117:109095. doi: 10.1016/j.biopha.2019.109095. Epub 
      2019 Jun 12.